Abstract
Objectives Despite the involvement of B cells in the pathogenesis of immune-mediated diseases, biological mechanisms underlying their function are scarcely understood. To overcome this gap, here we constructed and investigated a large-scale repertoire catalog of five B cell subsets of immune-mediated disease patients.
Methods We mapped B cell receptor regions from RNA sequencing data of sorted B cell subsets. Our dataset consisted of 595 donors under immune-mediated diseases and health. We characterized the repertoire features from various aspects, including their association with immune cell transcriptomes and clinical features and their response to belimumab treatment.
Results Heavy-chain complementarity-determining region 3 (CDR-H3) length among naïve B cells was shortened among autoimmune diseases. Strong negative correlation between interferon signature strength and CDR-H3 length was observed only in naïve B cells and suggested the role for interferon in pre-mature B cell development. VDJ gene usage was skewed especially in plasmablasts and unswitched-memory B cells of systemic lupus erythematosus (SLE) patients. We developed a scoring system for this skewing, and it positively correlated with peripheral helper T cell transcriptomic signatures and negatively correlated with the amount of somatic hyper mutations in plasmablasts, suggesting the association of extra-follicular pathway. Further, this skewing led to high usage of IGHV4-34 gene in unswitched-memory B cells, whose usage showed prominent positive correlation with disease activity in SLE. Gene usage skewing in unswitched-memory B cells was ameliorated after belimumab treatment.
Conclusions Our multimodal repertoire analysis enabled us the system-level understanding of B cell abnormality in diseases.
Competing Interest Statement
MO, YN, and TO belonged to the Social Cooperation Program, Department of functional genomics and immunological diseases, supported by Chugai Pharmaceutical. NB is an employee of Chugai Pharmaceutical. KF receives consulting honoraria and research support from Chugai Pharmaceutical.
Funding Statement
This study was supported by Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, the Center of Innovation Program from Japan Science and Technology Agency (JST) (JPMJCE1304), the Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED) (JP17ek0109103, 19ek0410047 and JP20ek0410074).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees of the University of Tokyo, the Jikei University School of Medicine, St. Luke's International Hospital, National Center for Global Health, and Medicine and Tokyo Metropolitan Komagome Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 1 and other associated materials have been revised to add the results from validation analysis with BCR-seq.
Data Availability
BCR data used in this study will be available at the National Bioscience Database Center (NBDC) Human Database (https://humandbs.biosciencedbc.jp/en/) at the time of publication.
